Vyant Bio Reports Second Quarter 2021 Results and Provides Strategic Business Updates
August 16, 2021 16:01 ET
|
Vyant Bio, Inc.
Strategic Highlights Received an issued US Patent titled “High Throughput Optical Assay of Human Mixed Cell Population Spheroids” by the United States...
Vyant Bio, Inc., Ordaōs Bio, and Cellaria, Inc. Announce Collaboration to Design and Qualify Biomarker-Specific Small Protein Therapeutics
April 22, 2021 08:00 ET
|
Vyant Bio, Inc.
New collaboration mitigates risk in drug discovery process with artificial intelligence and in vitro “avatar” clinical trials CHERRY HILL, N.J., April 22, 2021 (GLOBE NEWSWIRE) -- Vyant Bio, Inc....
Cellaria Adds Next-Generation RNA Reprogramming and Stem Cell Services
March 20, 2017 08:43 ET
|
Cellaria Bio
CAMBRIDGE, Mass., March 20, 2017 (GLOBE NEWSWIRE) -- Cellaria, LLC, a scientific innovator that develops revolutionary new cancer models for challenging tumors, today announced the expansion of its...
Cellaria Forms Strategic Partnership with AMS Biotechnology
February 09, 2017 12:11 ET
|
Cellaria Bio
CAMBRIDGE, Mass., Feb. 09, 2017 (GLOBE NEWSWIRE) -- Cellaria, LLC, a scientific innovator that develops revolutionary new patient-specific cancer models for challenging tumors, today announced the...
Cellaria to Release Novel Ovarian and Breast Cancer Cell Models
November 15, 2016 12:33 ET
|
Cellaria Bio
CAMBRIDGE, Mass., Nov. 15, 2016 (GLOBE NEWSWIRE) -- Cellaria, LLC, a scientific innovator that develops revolutionary new cancer models for challenging tumors, today announced the release of two new...